Xortx Therapeutics Inc. Stock
€2.41
Your prediction
Financial data and news for Xortx Therapeutics Inc.
sharewise wants to provide you with the best news and tools for Xortx Therapeutics Inc., so we directly link to the best financial data sources.
Financials
News
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
CALGARY, AB - April 30, 2024 - XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on
XORTX Announces Publication of Key Research in ADPKD
CALGARY, AB – April 22, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company
XORTX Welcomes New Member to the Board of Directors
CALGARY, AB – April 8, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company
XORTX Announces Participation in Spring 2024 Investor Conferences
CALGARY, AB – April 8, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company
XORTX Announces New Clinical Advisory Board Member
CALGARY, AB – March 27, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
CALGARY, AB – March 19, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
CALGARY, AB – March 11, 2024 – XORTX Therapeutics Inc. (“XORTX” or the “Company”)
XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
CALGARY, AB – March 4, 2024 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ:
XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
CALGARY, AB – February 15, 2024 – XORTX Therapeutics Inc. (“XORTX” or the “Company”)
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
CALGARY, AB – January 3, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on
XORTX Welcomes New Member to the Board of Directors
CALGARY, AB – January 2, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on
XORTX Announces US ATM Offering
CALGARY, AB – November 30, 2023 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on
XORTX Meets Nasdaq Continued Listing Requirements
CALGARY, AB – November 29, 2023 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on